Pfizer and the United States government have struck an agreement for Pfizer to producer millions of doses for its Covid-19 vaccine. Pfizer would deliver 100 million doses into the United States once the vaccine has been approved. CNBC’s “Squawk Box” crew discusses. For more coronavirus live updates: https://www.cnbc.com/2020/07/22/coronavirus-live-updates.html For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi
The vaccine would be free to Americans, according to the deal, though health care providers could charge to administer it.
Pfizer is working on the vaccine with BioNTech, a German company. Clinical trials began in April, and Pfizer announced positive early results this week, though it has yet to announce that data have been vetted and published in a medical journal. Larger safety and efficacy studies could begin later this month.
Pfizer Inc. and BioNTech SE are setting a price ceiling of less than $20 a dose that will impact how much other companies can charge to protect people from Covid-19.
Bloomberg reports that Pfizer’s $19.50 price-point takes into account the “public health requirements during the pandemic,” said Sally Beatty, a Pfizer spokeswoman. The companies are pursuing a two-dose regimen of one of its vaccine candidates, and the roughly $40 course, Beatty said, is “almost 30% less than what others charge for a seasonal flu vaccine.”
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Coronavirus Vaccine News From Google
- $SPY US Moving Closer to Double-Dip Recession Economist Warns - August 11, 2020
- $DLN Case for Value Stocks Is Rising, Strategist Shah Says - August 10, 2020
- $SPY Trump Executive Orders Not Enough Says Moodys - August 10, 2020